Andrew Hill Fund Sees Vertex Growth Beyond Cystic Fibrosis
The fund says Vertex’s cystic fibrosis cash flow supports investments in kidney disease, pain management and other specialty areas.
Key takeaways
- The fund says Vertex is expanding beyond its cystic fibrosis business through acquisitions and research.
- Its investments include kidney disease, pain management and gene editing.
Andrew Hill Investment Fund said Vertex Pharmaceuticals has growth drivers beyond its cystic fibrosis business, pointing to the company’s investments in other therapies.
In its third-quarter investor letter, the fund said Vertex’s cystic fibrosis franchise generates cash flow that helps support expansion into new therapeutic areas. It cited acquisitions and internal research in areas including kidney disease, pain management and gene editing.
The fund said it believes investors continue to view Vertex mainly through its cystic fibrosis business and underappreciate its developing portfolio of potential growth drivers.
This article was produced with the help of AI technology. Source: Yahoo Finance
